Leadership And ExpertiseJade Biosciences is led by the former Chinook team, known for its expertise, having sold its IgAN portfolio to Novartis for a substantial amount.
Market PotentialJADE-001 is anticipated to capture a significant share of the potential $10B+ IgAN market, with projected global sales reaching billions.
Product DevelopmentJADE101, a pure anti-APRIL mAb, shows remarkable potency at 755 times greater than competitors and offers a potentially longer dosing interval.